Metamizole outperforms meloxicam in sepsis: insights on analgesics, survival and immunomodulation in the peritoneal contamination and infection sepsis model
Metamizole and Meloxicam effectively relieved pain and increased the animals' basal activity in the PCI sepsis model. Meloxicam prolonged survival yet triggered maladaptive responses due to its immunosuppressive features that decreased tissue bacterial clearance during sepsis. In contrast, Metamizole constitutes a safe and effective non-opioid alternative for analgesic control in the non-surgical PCI sepsis model.
Authors
- Marc Thilo Figge (ORCID: https://orcid.org/0000-0002-4044-9166)
- Carl‐Magnus Svensson (ORCID: https://orcid.org/0000-0002-9723-9063)
- Sabine Bischoff (ORCID: https://orcid.org/0000-0002-1782-9494)
- Oliver Sommerfeld (ORCID: https://orcid.org/0000-0001-9625-1418)
- Michael Bauer (ORCID: https://orcid.org/0000-0002-1521-3514)
- Adrian Tibor Press (ORCID: https://orcid.org/0000-0002-6089-6764)
- Reinhard Bauer (ORCID: https://orcid.org/0000-0002-4294-3758)
- Marcin F. Osuchowski (ORCID: https://orcid.org/0000-0002-1321-9883)
- Na Liu (ORCID: https://orcid.org/0000-0001-9903-1314)
- Mitali Sonawane
Institutions
- Ludwig Boltzmann Institute for Traumatology, The Research Center in Cooperation with AUVA (AT)
- Jena University Hospital (DE)
- Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. - Hans-Knöll-Institut (HKI) (DE)
- Friedrich Schiller University Jena (DE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-08-30
- DOI
- https://doi.org/10.3389/fimmu.2024.1432307
- Citations
- 1
- Primary Topic
- Sepsis Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- Universitätsklinikum Jena
- Leibniz-Gemeinschaft